| Kuniko Limited (KNI) ORDINARY FULLY PAID |
Materials |
$6 |
Proposed issue of securities - KNI
|
31 Jul 2025 6:36PM |
$0.099 |
$0.029 |
fallen by
70.71%
|
|
| Osteopore Limited (OSX) ORDINARY FULLY PAID |
Health Care |
$3 |
Change in substantial holding
|
31 Jul 2025 6:34PM |
$0.011 |
$0.005 |
fallen by
54.55%
|
|
| Alara Resources Limited (AUQ) ORDINARY FULLY PAID |
Materials |
$27 |
Quarterly Activities and Cashflow Report
|
31 Jul 2025 6:33PM |
$0.033 |
$0.034 |
risen by
3.03%
|
|
AUQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Alara Resources continued construction and commissioning activities at the Al Hadeetha Copper-Gold Project in Oman.
- Copper concentrate production, shipments, and sales remained ongoing during the quarter.
- Key operational milestones were achieved, including plant ramp-up and concentrate grade improvements.
- Exploration programs continued at the Washihi and Mullaq prospects, with drilling and resource evaluation activities.
- Operational and capital costs were managed, with a focus on improving cashflow and financial performance.
- Corporate updates included financial results, cashflow statement, and forward-looking statements about project timelines and strategy.
- The report outlines the company’s strategic focus on maximizing value from its Oman assets and advancing project development.
- Community and stakeholder engagement activities were maintained as part of project operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Duxton Water Limited (D2O) ORDINARY FULLY PAID |
Utilities |
- |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 6:32PM |
$1.525 |
$1.530 |
risen by
0.33%
|
|
D2O - Price-sensitive ASX Announcement
Full Release
Key Points
- Duxton Water Limited released its Quarterly Activities and Appendix 4C Cash Flow Report for the period ending 31 March 2023.
- The company focuses on managing and trading water entitlements and leasing arrangements to agricultural customers.
- During the quarter, water market activity was influenced by favorable seasonal conditions and strong commodity prices.
- Duxton Water engaged in both permanent and temporary water entitlement trades, with a noted increase in lease activity.
- Receipts from customers for the quarter were reported at approximately $3.9 million.
- Operating cash outflows totaled approximately $0.5 million.
- The company held a diverse water portfolio across several catchments, primarily in the southern connected Murray-Darling Basin.
- A strong balance sheet is maintained with sufficient liquidity and undrawn bank facilities to support future operations.
- There were no material changes in business activities outside the ordinary course of operations.
- The report includes statements on risk management, corporate governance, and compliance with regulatory obligations.
- Duxton Water intends to continue providing water solutions to support the agricultural sector and optimize portfolio returns.
- No payments were made to related parties other than usual director remuneration.
- The company remains focused on disciplined capital management and intends to pursue further growth opportunities in line with its strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Parabellum Resources Limited (PBL) ORDINARY FULLY PAID |
Materials |
$4 |
Appendix 4G - Corporate Governance Principles
|
31 Jul 2025 6:31PM |
$0.055 |
$0.060 |
risen by
9.09%
|
|
| New World Resources Limited (NWC) ORDINARY FULLY PAID |
Materials |
- |
Application for quotation of securities - NWC
|
31 Jul 2025 6:30PM |
$0.067 |
$0.067 |
fallen by
0%
|
|
| BPH Global Ltd (BP8) ORDINARY FULLY PAID |
Health Care |
$4 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 6:30PM |
$0.002 |
$0.002 |
fallen by
25%
|
|
BP8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers period ending 31 March 2024
- Focus on BP8 bioproducts development and commercialization
- Progress in product registration and regulatory approvals
- Establishment and expansion of distribution networks
- Cash flows directed to operating expenses, R&D, and corporate costs
- Reported cash receipts and net cash outflows for the quarter
- Outlined strategic priorities for market expansion
- Maintained compliance and strong financial management
- Included related party transactions and use of funds statement
- Continued engagement with investors and stakeholders
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kuniko Limited (KNI) ORDINARY FULLY PAID |
Materials |
$6 |
Proposed issue of securities - KNI
|
31 Jul 2025 6:29PM |
$0.099 |
$0.029 |
fallen by
70.71%
|
|
| New World Resources Limited (NWC) ORDINARY FULLY PAID |
Materials |
- |
Exercise of Performance Rights
|
31 Jul 2025 6:29PM |
$0.067 |
$0.067 |
fallen by
0%
|
|
| Bridge SaaS Limited (BGE) ORDINARY FULLY PAID |
Information Technology |
$4 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 6:28PM |
$0.019 |
$0.020 |
risen by
5.26%
|
|
BGE - Price-sensitive ASX Announcement
Full Release
Key Points
- Bridge SaaS Limited advanced its product development and continued onboarding new clients during the quarter.
- Ongoing engagement with key sales partners was maintained.
- The company invested in enhancing its SaaS platform, expanding features and improving user experience.
- Cost-saving initiatives and operational efficiencies were implemented to optimize business operations.
- The Appendix 4C Cash Flow Report shows net cash used in operating activities for the quarter.
- Management provided commentary on the company’s cash position and outlook, including sufficient funding for planned activities.
- Future business objectives and planned activities for the next quarter were outlined.
- Compliance with ASX listing rules and confirmation of related party payments were included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 8Common Ltd (8CO) ORDINARY FULLY PAID |
Information Technology |
$9 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 6:28PM |
$0.021 |
$0.040 |
risen by
90.48%
|
|
8CO - Price-sensitive ASX Announcement
Full Release
Key Points
- SaaS revenue continues to grow, with quarterly receipts up from previous periods.
- Secured new contracts and renewals, notably in the government sector, including a Department of Education contract.
- Expense8 and CardHero platforms are expanding, with a focus on new features and broader applications such as payroll and disbursement.
- The company achieved positive operational cash flow for the quarter.
- Product development investment remains strong, especially for CardHero’s enhancements.
- Customer implementations are progressing on schedule, contributing to near-term revenue.
- Outlook remains positive with a pipeline of new opportunities and ongoing product innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dalaroo Metals Ltd (DAL) ORDINARY FULLY PAID |
Materials |
$25 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jul 2025 6:28PM |
$0.029 |
$0.073 |
risen by
151.72%
|
|
DAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Dalaroo Metals Ltd lodged its Quarterly Activities/Appendix 5B Cash Flow Report for the period ending 31 March 2023.
- Key exploration focus was maintained on the Namban and Lyons River Projects, targeting nickel-copper-PGE and base metals.
- Field activities included detailed soil sampling and geophysical surveys to refine targets for future drilling.
- Exploration and evaluation expenditure was the major outflow, with no revenue from sales or production reported.
- Administrative and staff costs are detailed, with overall net cash outflows for the quarter.
- Dalaroo Metals remains funded for ongoing exploration activities and is evaluating additional project opportunities.
- The report includes an Appendix 5B summarizing cash flows for the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Althea Group Holdings Limited (AGH) ORDINARY FULLY PAID |
Health Care |
- |
Cleansing Prospectus
|
31 Jul 2025 6:26PM |
$0.026 |
$0.020 |
fallen by
23.08%
|
|
| Osteopore Limited (OSX) ORDINARY FULLY PAID |
Health Care |
$3 |
Application for quotation of securities - OSX
|
31 Jul 2025 6:25PM |
$0.011 |
$0.005 |
fallen by
54.55%
|
|
| Parabellum Resources Limited (PBL) ORDINARY FULLY PAID |
Materials |
$4 |
Corporate Governance Statement
|
31 Jul 2025 6:24PM |
$0.055 |
$0.060 |
risen by
9.09%
|
|
| Kuniko Limited (KNI) ORDINARY FULLY PAID |
Materials |
$6 |
Entitlement Issue Prospectus
|
31 Jul 2025 6:24PM |
$0.099 |
$0.029 |
fallen by
70.71%
|
|
KNI - Price-sensitive ASX Announcement
Full Release
Key Points
- Kuniko Limited is conducting a non-renounceable entitlement issue to raise up to approximately $2.8 million.
- Eligible shareholders are offered 1 new share for every 12 existing shares held, at an issue price of $0.30 per share.
- Funds raised will support exploration and development of Kuniko’s battery metals projects in Europe.
- The main focus is on nickel, cobalt, copper, and lithium assets in Norway and other European locations.
- The offer is not underwritten and participation is voluntary for eligible shareholders.
- The prospectus details the use of funds, including project development, working capital, and offer costs.
- Risks outlined include exploration risks, commodity prices, regulatory challenges, and market volatility.
- Applicants are advised to read the entire prospectus and consult professional advisers before investing.
- Key dates, instructions on how to apply, and company contact information are provided.
- Directors intend to participate in the offer and support the company’s growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Conico Ltd (CNJ) ORDINARY FULLY PAID |
Materials |
$5 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jul 2025 6:23PM |
$0.007 |
$0.008 |
risen by
14.29%
|
|
CNJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Conico Ltd settled a legal dispute with Cartwright Drilling Inc, paying CAD$322,500.
- The company raised $900,000 through unsecured convertible loans.
- Conico intends to raise an additional $500,000 via a placement managed by RM Corporate Finance Pty Ltd.
- The funds raised will support working capital and exploration expenses for projects in Greenland and Australia.
- Conico is examining opportunities for its Mestersvig and Ryberg projects in Greenland.
- No exploration or mining production activities occurred during the quarter due to focus on legal and corporate compliance.
- The company plans to resume trading on the ASX after finalizing capital raising and satisfying ASX requirements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Conico Ltd (CNJ) ORDINARY FULLY PAID |
Materials |
$5 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jul 2025 6:23PM |
$0.007 |
$0.008 |
risen by
14.29%
|
|
CNJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Settlement of legal dispute with Cartwright Drilling.
- Net cash outflow from operating activities.
- Issued $900,000 in convertible loans.
- Plans to raise additional $500,000 in capital.
- Projects in Greenland and Australia to benefit from new funding.
- Cash position improved by financing activities.
- No related party payments during the quarter.
- Future development plans for Mt Thirsty Joint Venture.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| identitii Limited (ID8) ORDINARY FULLY PAID |
Information Technology |
$3 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 6:22PM |
$0.006 |
$0.003 |
fallen by
50%
|
|
ID8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities Report and Appendix 4C released for Q3 FY24 ended 31 March 2024.
- Ongoing customer engagement and onboarding for cloud-based reporting platform.
- Product enhancements to support new payment reporting requirements, including international payments.
- Development continues on PayVu, a payments automation solution.
- Receipts from customers and government grants reported.
- Active exploration of capital raising opportunities to support growth and development.
- Focus remains on regulatory technology solutions for the financial sector.
- Company maintains a strong cash position as of quarter end.
- Strategy includes expanding market presence both domestically and internationally.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Infini Resources Limited (I88) ORDINARY FULLY PAID |
Materials |
$12 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jul 2025 6:21PM |
$0.170 |
$0.115 |
fallen by
32.35%
|
|
I88 - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden diamond drilling program completed at Lake Johnson Project with pegmatite intersections in all holes.
- Exploration activities advanced at the Tambourah Lithium Project.
- Desktop review and development work at Canadian projects.
- Raised $1.26 million via placement, with $1.67 million cash balance at quarter end.
- Exploration and evaluation expenditure of $310k for the quarter.
- Administration and corporate costs totaled $143k.
- No production or development activities during the quarter.
- No mining tenements acquired or disposed during the quarter.
- No related party payments other than directors’ fees and consulting fees.
- Focus remains on progressing lithium, REE, and uranium exploration projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Infocus Group Holdings Limited (IFG) ORDINARY FULLY PAID |
Information Technology |
$4 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 6:20PM |
$0.016 |
$0.007 |
fallen by
56.25%
|
|
IFG - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities Report and Appendix 4C Cash Flow Report released for the quarter ending 31 March 2024.
- Business operations focused on education and training services in China.
- Updates on business development, customer engagement, and program expansion.
- Ongoing efforts to improve operational efficiency and cost management.
- Impact of regulatory and market conditions discussed.
- Provided summary of cash flow and financial position for the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$20,588 |
PME signs finance facility with 4DMedical
|
31 Jul 2025 6:19PM |
$321.890 |
$197.070 |
fallen by
38.78%
|
|
PME - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro Medicus Limited announces a finance facility with 4DMedical.
- The agreement supports 4DMedical's lung function imaging and analysis products.
- The announcement was made by Pro Medicus Limited on 31 July 2025.
- The collaboration is expected to drive the development and commercialization of 4DMedical's software.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$20,588 |
PME signs finance facility with 4DMedical
|
31 Jul 2025 6:19PM |
$321.890 |
$197.070 |
fallen by
38.78%
|
|
PME - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro Medicus Limited announced a financing arrangement with 4DMedical.
- The facility is intended to aid in the development and commercialization of 4DMedical's software products.
- The announcement was made on 31 July 2025.
- 4DMedical's products include lung function imaging and analysis tools.
- The announcement was authorized by the Board of Pro Medicus Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noumi Limited (NOU) ORDINARY FULLY PAID |
Consumer Staple |
$30 |
Appendix 4C for the Qtr Ended 30 June 2025
|
31 Jul 2025 6:19PM |
$0.130 |
$0.110 |
fallen by
15.38%
|
|
NOU - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly cash flow report for Noumi Limited ended 30 June 2025.
- Detailed breakdown of cash flows from operating, investing, and financing activities.
- Emphasis on operational improvements and cost control measures.
- Update on strategic initiatives to strengthen financial position.
- Commentary on liquidity, business performance, and risk management.
- Discussion of sector and market challenges impacting the business.
- Outline of key risks and mitigation strategies.
- Management’s outlook and focus areas for the next quarter.
- Stakeholder update on company progress and future priorities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$115 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 6:18PM |
$0.388 |
$0.385 |
fallen by
0.65%
|
|
RCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Recce Pharmaceuticals Ltd released its Quarterly Activities/Appendix 4C Cash Flow Report for quarter ending 31 December 2023.
- RCE advanced clinical trials for RECCE® 327 (R327) in both topical and intravenous forms targeting bacterial infections, achieving key milestones.
- Progress was also reported on RECCE® 529 (R529) development.
- The company collaborated with various research institutions and regulatory authorities to further its anti-infective programs.
- Financially, RCE ended the quarter with $8.8 million in cash and cash equivalents.
- Cash reserves are anticipated to support planned activities through Q4 of calendar year 2024.
- Expenditure mainly consisted of routine operating costs, research and development, and director fees, with no other significant related party payments reported.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
